Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies

Wolf, Sherry L.; Barton, Debra L.; Kottschade, Lisa A.; Grothey, Axel; Loprinzi, Charles L.

doi:10.1016/j.ejca.2008.04.018

Cited by 552 publications

(407 citation statements)

References 57 publications

Supporting

Mentioning

383

Contrasting

Unclassified

Order By: Relevance

“…In general, 30–40% of chemotherapy patients develop a painful peripheral neuropathy, though the incidence and severity greatly differs between drugs (Wolf et al. 2008; Hershman et al. 2014).…”

Section: Introductionmentioning

confidence: 99%

Pharmacological comparison of a nonhuman primate and a rat model of oxaliplatin‐induced neuropathic cold hypersensitivity

Shidahara

Ogawa

Nakamura

et al. 2016

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Oxaliplatin is a first‐line treatment for colorectal cancer. However, shortly following treatment, cold‐evoked hypersensitivity appears in the extremities and over time, the pain is such that oxaliplatin dosing may need to be markedly reduced or even terminated. There is currently a lack of efficacious treatments for oxaliplatin‐induced peripheral neuropathy, which is due in part to the difficulty in translating findings obtained from preclinical rodent models of chemotherapy‐induced peripheral neuropathy. Nonhuman primates (NHP) are phylogenetically closer to humans than rodents and may show drug responses that parallel those of humans. A significant decrease in tail withdrawal latency to 10°C water (“cold hypersensitivity”) was observed beginning 3 days after intravenous infusion of oxaliplatin (5 mg/kg) in Macaca fascicularis. A single treatment of duloxetine (30 mg/kg, p.o.) ameliorated oxaliplatin‐induced cold hypersensitivity, whereas pregabalin (30 mg/kg, p.o.) and tramadol (30 mg/kg, p.o.) did not. By contrast, in rats, no significant cold hypersensitivity, or increased responsiveness to acetone applied to the hind paws, was observed 3 days after the first injection of oxaliplatin (5 mg/kg, i.p., once per day, two injections). Therefore, rats were tested after six treatments of oxaliplatin, 17 days after the first treatment. All analgesics (30 mg/kg, p.o.) significantly ameliorated cold hypersensitivity in rats. The activity of analgesics in the oxaliplatin‐treated macaques parallel clinical findings. The current results indicate that the NHP could serve as a bridge species to improve translatability of preclinical findings into clinically useful treatments for oxaliplatin‐induced peripheral neuropathy.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacological comparison of a nonhuman primate and a rat model of oxaliplatin‐induced neuropathic cold hypersensitivity

Shidahara

Ogawa

Nakamura

et al. 2016

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…Chemotherapy-induced peripheral neuropathy (CIPN) can occur in 10-40% of patients treated with neurotoxic chemotherapy and is often a dose-limiting side effect. 10 A retrospective study of the SEER-Medicare database showed that patients who received taxane-based chemotherapy are twice as likely to develop CIPN and patients treated with taxane-platinum chemotherapy combinations are 3 times as likely to develop CIPN compared to similar patients with cancer who did not receive chemotherapy. 11 Deficits caused by CIPN can include loss of sensation to touch, pinprick, and vibratory sensation and more commonly affect nerves in the lower extremities.…”

Section: Introductionmentioning

confidence: 99%

Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: A retrospective cohort study

Ward

Wong

Moore

et al. 2014

Journal of Geriatric Oncology

View full text Add to dashboard Cite

show abstract

“…Furthermore, in patients with hematologic malignancies who have been administered neurotoxic chemotherapeutic agents, CIPN assessment must accompany a comparison of the lower and upper extremity symptoms [21]. Moreover in this study, the lower extremity scale scores were significantly different with re- [11,21,28] that reported that CIPN level is related to age, ECOG PS, duration of diagnosis, duration of CIPN, and exposure to neurotoxic chemotherapeutic agents. Therefore, the variables that led to differential scores in the lower-extremity peripheral neuropathy section should be incorporated into the education and counseling materials for patients with hematologic malignancies who have been administered neuro-toxic chemotherapeutic agents.…”

Section: Discussionmentioning

confidence: 62%

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

Song

Kim

Lee

2015

Korean J Adult Nurs

View full text Add to dashboard Cite

Purpose: This study was aimed to identify the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) among patients with hematologic malignancies and to examine the relationship between the quality of life (QOL) and CIPN. Methods: A total of 66 patients with CIPN-related symptoms participated in this study. Data were collected through self-reported questionnaires consisted of the European Organization for Research and Treatment of Cancer QLQ-C30 version 3.0 and the 16-item QLQ-CIPN20. Data were analyzed with SPSS/ WIN20 for descriptive statistics using the Mann-Whitney and Kruskal-Wallis tests, and Spearman's rho. Results: The mean lower and upper extremity scale scores were 31.95 and 23.16 respectively for the 16-item QLQ-CIPN20. The mean QLQ-C30 subcategory scores were 46.84 for global health status, 58.72 for functional scales, and 34.85 for symptom scales. The CIPN-related lower extremity scale symptoms correlated negatively with the QOL subscales. There was no correlation between CIPN-related upper extremity symptoms and health-related QOL. Conclusion: Patients with hematologic malignancies treated with neurotoxic chemotherapeutic agents had CIPN-related symptoms in the lower extremities mainly, and their QOL functional subscale scores were relatively lower than those of other cancer patients. Interventions need to be developed for patients with hematologic malignancies to alleviate CIPN and enhance their QOL.

show abstract

Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies

Cited by 552 publications

References 57 publications

Pharmacological comparison of a nonhuman primate and a rat model of oxaliplatin‐induced neuropathic cold hypersensitivity

Pharmacological comparison of a nonhuman primate and a rat model of oxaliplatin‐induced neuropathic cold hypersensitivity

Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: A retrospective cohort study

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

Contact Info

Product

Resources

About